Electrochemotherapy in melanoma patients: a single institution experience [0.03%]
黑色素瘤患者的电化学治疗：一家机构的经验报告
Corrado Caracò,Ugo Marone,Ester Simeone et al.
Corrado Caracò et al.
Aim: This study was undertaken to update the outcome of the treated lesions with electrochemotherapy (ECT) plus intravenous injection of bleomycin in patients with in-transit disease or distant cutaneous metastases in mel...
Sandeep Batra
Sandeep Batra
Spitzoid melanomas (SM) and atypical Spitz tumors (AST) are rare pediatric neoplasms. We performed a retrospective, single-institution review and report our institutional experience. We identified 10 patients (median age: 12.5 years). A sen...
Case Reports
Melanoma management. 2015 May;2(2):121-125. DOI:10.2217/mmt.15.6 2015
Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for BRAF-mutant melanoma: a case report [0.03%]
关于BRAF突变型黑色素瘤患者使用BRAF/MEK抑制剂治疗后出现肠道穿孔及快速缓解的一例报告
Samantha L Kass,Allison F Linden,Patrick G Jackson et al.
Samantha L Kass et al.
Combination BRAF/MEK inhibition has shown improved response rates and longer progression-free and overall survival for patients with BRAF-mutant metastatic melanoma. A 63-year-old female with widely metastatic BRAF V600E-mutant melanoma was...
Case Reports
Melanoma management. 2015 May;2(2):115-120. DOI:10.2217/mmt.15.10 2015
Vincenzo Villani,Francesco Sabbatino,Cristina R Ferrone et al.
Vincenzo Villani et al.
Brad Thompson
Brad Thompson
Oncolytics Biotech® Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company's lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is in late-stage clinical testing in a ran...
Sanjiv S Agarwala
Sanjiv S Agarwala
Melanomas' fatal attraction to lysophosphatidic acid trails: a new prognostic and therapeutic approach? [0.03%]
黑色素瘤对溶血磷脂酸轨迹的致命吸引力：一个新的预后和治疗途径？
Andrew J Muinonen-Martin,Robert H Insall
Andrew J Muinonen-Martin
Dynamic tumor heterogeneity in melanoma therapy: how do we address this in a novel model system? [0.03%]
黑色素瘤治疗中的肿瘤异质性动态：我们在新模型系统中如何应对？
Nikolas K Haass
Nikolas K Haass
Kachiu C Lee,H William Higgins nd,Abrar A Qureshi
Kachiu C Lee
The genetic risk factors for melanoma are complex and involve both familial and environmental components. Of the thousands of melanomas diagnosed each year, only a fraction are due to familial causes. These melanomas typically present in yo...
Pharmacist's role in optimizing therapy of the newer agents for the treatment of metastatic melanoma [0.03%]
新药物治疗转移性黑色素瘤的药剂师作用优化疗法中的角色
Gabriel Gazzé
Gabriel Gazzé
Metastatic melanoma is a disease with a historically dismal survival of 6-9 months with treatment. It is considered an incurable disease and resistant to conventional chemotherapy. We have learned much about the role of newer targets in the...